Bioxytran (BIXT) Stock Price, Financials & Analysis

Key Stats

Market Cap2.29 Mn

P/E-0.65

Total Debt (Qtr)1.16 Mn

Add ratio to table…

About

Bioxytran, Inc is a clinical stage pharmaceutical company developing platform technologies in glycovirology hypoxia and degenerative diseases to eliminate viruses and prolong lifespan using carbohydrate drug design. The company was incorporated on June 9 2008 as America s Driving Ranges Inc and was reorganized into Bioxytran on September 21 2018 through a reverse merger to focus on the development manufacturing and commercialization of therapeutic drugs for hypoxia…

The company expects to generate revenue from the sale of its therapeutic drug candidates once they receive regulatory approval and from licensing agreements with larger pharmaceutical partners. Revenue may also arise from collaborations and royalty arrangements related to its proprietary carbohydrate drug design and oxygen carrier platforms.

The company operates through the following segments.

Pharmalectin Inc focuses on the development manufacture and commercialization of therapeutic drugs for viral diseases.
NDPD Pharma Inc focuses on prototyping and development of specialized equipment for pharmaceutical manufacturing and on the development of carbohydrate molecules derived from partially hydrolyzed guar gum.
Pharmalectin BVI Inc serves as custodian of the company s copyrights trademarks and patents.
Pharmalectin India Pvt Ltd manages the company s local clinical research and trials and holds the local rights to commercialization in India.

Bioxytran occupies a niche position in the biopharmaceutical industry by focusing on carbohydrate based drug design for glycovirology and oxygen carrier therapeutics. The company s competitive advantages stem from its founder s decades of research on galectin proteins and its portfolio of issued patents that protect its platform technologies. While direct competitors are limited the company faces broader competition from other firms developing antiviral treatments and oxygen therapeutic agents.

The company intends to serve hospitals patients and healthcare providers that require antiviral treatments and oxygen therapeutic products. It also plans to partner with large pharmaceutical companies for licensing and distribution of its drug candidates. No specific customer names are disclosed in the filing.

How Bioxytran ranks

Ranked against the 673 companies in Pharmaceuticals and Biotechnology58 metrics · as of Oct 16, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −0.65xMedian 17.3x 18^th
P/FCFNegative free cash flow −2.62xMedian 17.9x 34^th
P/Operating cash flowNegative operating cash flow −2.62xMedian 16.4x 33^rd
P/S —Median 9.48x No data —
P/BNegative shareholder equity −0.46xMedian 2.17x Not meaningful —
P/Tangible bookNegative tangible equity −0.45xMedian 2.41x Not meaningful —
EV/EBITDA —Median 16.1x No data —
EV/EBITNegative EBIT −0.89xMedian 19.7x 23^rd
EV/Revenue —Median 6.87x No data —
EV/FCFNegative free cash flow −3.75xMedian 19.3x 39^th
EV/Operating cash flowNegative operating cash flow −3.75xMedian 16.2x 38^th
PEG (3Y EPS CAGR)Negative earnings 0.09Median 0.35 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) —Median 10.1% No data —
Revenue CAGR (3Y) —Median 10.1% No data —
Gross profit growth (1Y) —Median 10.6% No data —
Gross profit CAGR (3Y) —Median 10.7% No data —
Operating income growth (1Y) −135%Median −0.5% 9^th
Operating income CAGR (3Y) −8.5%Median 1.5% 36^th
Net income growth (1Y) −41.9%Median −6.1% 31^st
Net income CAGR (3Y) −1.6%Median −1.2% 49^th
EPS growth (1Y) −10.2%Median 20.8% 30^th
EPS CAGR (3Y) −7.5%Median 25.2% 23^rd
Operating cash flow growth (1Y) −97.8%Median 0.0% 10^th
Operating cash flow CAGR (3Y) 10.4%Median 2.4% 64^th
Free cash flow growth (1Y) −97.8%Median 0.0% 10^th
Free cash flow CAGR (3Y) 10.4%Median 3.2% 63^rd

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin —Median 73.3% No data —
EBITDA margin —Median −223% No data —
Operating margin —Median −238% No data —
Pretax margin —Median −229% No data —
Net margin —Median −233% No data —
FCF margin —Median −174% No data —
Operating cash flow margin —Median −170% No data —
Return on equity —Median −54.1% No data —
Return on assets −737%Median −42.2% 2^nd
Return on invested capital —Median −5.3% No data —
Return on capital employed —Median −46.5% No data —
Asset turnover —Median 0.18x No data —
Cash conversion (OCF / net income)Net income is not positive 0.25xMedian 1.20x Not meaningful —
Stock comp / revenue —Median 27.7% No data —

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets 348%Median 20.0% 2^nd
Debt / equityNegative shareholder equity −0.23xMedian 0.26x Not meaningful —
Net debt / EBITDA —Median 1.82x No data —
Debt / FCFFree cash flow is not positive −1.33xMedian 3.03x Not meaningful —
Liabilities / assets 1,582%Median 32.8% 2^nd
Equity / assetsNegative shareholder equity −1,482%Median 67.2% 2^nd
Interest coverage −25.5xMedian −10.2x 41^st
Current ratio 0.03xMedian 4.47x 1^st
Quick ratio 0.03xMedian 3.69x 3^rd
Cash ratio 0.03xMedian 3.33x 4^th
Altman Z-score —Median −0.74 No data —

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,131.24 Bn	42.35	14.20	54.91 Bn
2	JNJ	Johnson & Johnson	614.68 Bn	29.22	6.28	49.04 Bn
3	ABBV	AbbVie Inc.	503.28 Bn	79.76	7.82	70.82 Bn
4	MRK	Merck & Co., Inc.	368.01 Bn	115.98	5.53	53.91 Bn
5	NVS	Novartis Ag	298.43 Bn	18.92	5.45	9.59 Bn
6	AZN	Astrazeneca Plc	261.67 Bn	25.05	4.46	32.35 Bn
7	AMGN	Amgen Inc	236.03 Bn	27.00	6.20	57.30 Bn
8	BIXT	Bioxytran, Inc	0.00 Bn	-0.65	-	0.00 Bn

Bioxytran BIXT

About

How Bioxytran ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Bioxytran BIXT

About

How Bioxytran ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password